
May 31 (Reuters) - Novocure Ltd NVCR.O:
RESULTS FROM THE PHASE 3 PANOVA-3 TRIAL OF NOVOCURE’S TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR PANCREATIC CANCER TO BE PRESENTED AT 2025 ASCO ANNUAL MEETING
NOVOCURE LTD - TTFIELDS THERAPY SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR PANCREATIC CANCER
NOVOCURE LTD - TO FILE FOR FDA APPROVAL OF TTFIELDS THERAPY IN H2 2025
NOVOCURE LTD - PANOVA-3 TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN MEDIAN OS
NOVOCURE LTD - TTFIELDS THERAPY IMPROVES ONE-YEAR SURVIVAL RATE TO 68.1%